Purpose: To investigate the coupling of radiobiological models with patient-specific Monte Carlo (MC) dose calculations for permanent implant prostate brachytherapy (PIPB). To compare radiobiological indices evaluated with different radiobiological models using MC and simulated AAPM TG-43 dose calculations. Methods: Three-dimensional dose distributions previously computed using MC techniques with two types of patient models, TG43sim (AAPM TG-43 water-based conditions) and MCDmm (realistic tissues and interseed effects), for 613 PIPB patients are coupled with biological dose and tumour control probability (TCP) models. Two approaches and their extensions are considered to evaluate biological doses, biologically effective dose (BED) and isoeffective dose (IED), as well as two methods to evaluate TCP. Three novel extensions of equivalent uniform biologically effective dose (EUBED) are suggested which consider the spatial distribution of doses within the target volume. Adopted radiobiological model parameter values (a, b, etc) are those suggested by AAPM TG-137, and sensitivity to parameter choice is discussed. Results: MCDmm dose calculations can reveal low doses in the prostate target volume, due to tissue heterogeneities or inter-seed effects; considering these low doses in EUBED calculations can lower TCP estimates by up to 70%, with largest differences in patients with calcifications. There are large variations in biological doses and TCPs evaluated over the 613 patient cohort for each radiobiological model considered, reflecting the spectrum of physical doses calculated for these patients with either MCDmm or TG43sim. Depending on the model details, BED, IED and EUBED are, on average, 6.0-9.8%, 7.4-9.2% and 1.8-15% higher, respectively, with TG43sim than MCDmm. TCP estimates computed using MCDmm dose distributions are much lower than expected based on past treatment outcome studies, suggesting a need to re-assess model parameters when evaluating radiobiological indices coupled with heterogeneous tissue model-based dose calculations. Conclusions: Cohort average differences in biological dose and TCP estimates between radiobiological models are generally larger than differences for any one radiobiological model evaluated with TG43sim or MCDmm dose calculations. However, heterogeneous tissue dose calculations, like MCDmm, can identify clinically-relevant low dose volumes, e.g., in patients with calcifications, which would otherwise be missed with TG-43. In addition to affecting physical dose distributions, these low dose volumes can largely impact radiobiological dose and TCP estimates, which further motivates the clinical implementation of model-based dose calculations for PIPB.
INTRODUCTION
The current clinical standard for permanent implant prostate brachytherapy (PIPB) dose calculations follows the AAPM TG-43 formalism, 1 but these calculations approximate the patient as homogeneous water, neglecting tissue composition, interseed attenuation, and scattering effects. More accurate model-based dose calculations can account for realistic tissues and interseed effects, for example, Monte Carlo (MC) simulations in a detailed virtual patient model. The AAPM-ESTRO-ABG TG-186 report 2 endorsed model-based dose calculations for brachytherapy, providing guidelines for their clinical implementation. Recently, we completed a retrospective MC dosimetric study for a large cohort of 125 I PIPB patients, and demonstrated differences of several percent between calculations performed with TG-43 and realistic tissue conditions (target volume D 90 is lower by 5.9% on average with full-tissue MC compared to TG-43), with larger differences in patients with prostatic calcifications (D 90 up to 25% lower). 3 The physical dose distribution remains the primary metric of treatment quality, but radiobiological indices are of increasing clinical interest. 4, 5 Although radiobiological modeling may provide insight by accounting for biological response to radiotherapy, these models are limited by their requirement to assume particular mechanistic forms and rely on several largely uncertain biological and patient-specific parameters. In an attempt to establish a consensus approach, the AAPM Task Group 137 report 4 presented a detailed summary of numerous PIPB radiobiological models and recommended parameter values. However, there is currently no published work which compares several radiobiological models using TG-43 and realistic tissue condition MC dose calculations in a large cohort of PIPB patients.
The purpose of this work is to investigate the coupling of patient-specific MC dose calculations with existing PIPB biological dose and tumor control probability models. Radiobiological model predictions are compared between retrospective MC dose calculations in full tissue with interseed effect models and simulated TG-43 models for 613 PIPB patients treated between 2003 and 2012 at CHU de Qu ebecUniversit e Laval. Since radiobiological models vary considerably across the literature, we consider several published models of varied complexity using a consistent set of biological parameters. We identify new issues related to incorporating dose calculation models which consider tissue heterogeneities and ISA, and suggest extensions to enable existing radiobiological models to better account for possible dosimetric effects. Finally, we discuss the sensitivity of radiobiological indices to various assumed model parameters and identify a need to readjust existing parameter recommendations to allow radiobiological models coupled with full-tissue MC dose calculations to reflect observed PIPB treatment outcomes.
METHODS AND MATERIALS

2.A. Radiobiological models
Biological dose represents tissue-specific biological response to radiation damage over protracted radiotherapy treatments. We compare two methods (and their extensions) to compute biological doses for PIPB patients: the biologically effective dose (BED) and the isoeffective dose (IED). Additionally, we compare two methods to evaluate tumor control probability (TCP) which is the clinical endpoint of interest and describes the likelihood of a treatment to be curative. These radiobiological models depend on biological parameters which are generally unknown for a given patient, so we assume a set of literature-derived values (Table I) unless noted otherwise.
The well-adopted 4,7-10 PIPB BED formalism presented by Dale 11, 12 is a product of the physical dose and its relative effectiveness, corrected by a repopulation factor which assumes continuous, uniform, exponential tumor growth during the treatment time. BED is often evaluated at a particular time, T eff , which is when the rate of cell repopulation surpasses the exponentially decreasing rate of cell kill as the radionuclide decays:
where
and R 0 is the dose rate (other parameters defined in Table I ). Implementations of BED vary across the literature, for example, Stock et al. 7 did not consider the repopulation term in Eq. (1) and assumed a uniform delivery of the patient-specific D 90 , whereas Ling et al. 13 assumed a uniform delivery of D 99 .
Equation (3) assumes dose rate (R 0 ) is constant throughout the target volume, which is untrue for low-energy brachytherapy dose distributions. Accounting for dose rate is important when modeling biological response since cells require time to repair damage and repopulate. In fact, with no cell proliferation and instantaneous cell repair, BED simplifies to the total physical dose. Ling et al. 13 showed that accounting for dose rate may change the biological dose by up to 70% and proposed a method to account for nonuniform dose distributions by evaluating BED separately for each isodose volume, which may be determined from the bins of a differential dose volume histogram (dDVH). The equivalent uniform BED (EUBED) is defined as
where m i is the fraction of the target volume which receives the isodose BED i , and the sum of all m i is 1. EUBED has been supported by TG-137 4 and implemented by several investigators. [13] [14] [15] [16] [17] Biologically effective dose (and EUBED) are often used to calculate TCP from binomial (specifically, Poisson) statistics. If n cells are exposed to a dose D, then a fraction S(D) will survive. For the next n cells exposed to a dose D, the possible range of surviving cells is anywhere between 0 and n, but on average there will be nS(D) survivors,
The Poisson TCP formalism, 4 TCP P , can be evaluated at the effective treatment time, T eff , by assuming N 0 uniformly distributed initial cancerous cells (discussed in Sections IV C and IV D) that are subjected to a biological dose (ex. BED),
The mechanistic form of TCP P may be unrealistically steep, and Dasu et al. 18 showed that TCP models may better fit clinical outcomes when parameters, such as a, are modeled as distributions, rather than single values. Webb and Nahum 19 proposed to model a distributions by sampling a from a normal distribution (we adopt 10 5 samples) which effectively broadens the TCP P curve into what we will refer to as the broad TCP (TCP B ),
The a broadening factor, representing inter and intratumoral variations in cellular response to radiation, has been suggested to be 0.04 Gy À1 20 or 0.08 Gy
, but we have assumed a lower value of 0.025 Gy À1 to mitigate overflattening of the TCP B curve. Haworth et al. 15 investigated the use of low a cutoffs and log-normal (rather than Gaussian) a distributions, neither of which are used in this work.
A second approach to evaluate biological dose and TCP is described by Zaider et al. 6, 22 which utilizes the linear quadratic dose response (LQ) and considers natural cell proliferation and death rates explicitly. Cell surviving fraction may be described by the linear quadratic (LQ) function if one accounts for the effects of dose rate by introducing a term q(t) in front of b. The term b describes the yield of cell kill caused by two separate tracks of radiation, and is influenced by dose rate since a higher dose rate would increase the probability of the second track occurring before the first is repaired. The LQ surviving fraction and PIPB q(t) are,
qðtÞ ¼ 2ðktÞ
Zaider and Hanin 22 extended this to calculate an isoeffective dose (IED), 22 which is conceptually similar to BED,
Zaider and Hanin 22 showed evaluating IED at T eff may underestimate TCP, and suggest IED be evaluated at infinite time, which we practically estimate as ten 125 I half lives (10t 1/2 = 594 days).
Zaider and Minerbo 6 presented a generalized TCP formalism which may be applied to permanent implant brachytherapy, here denoted TCP Z :
This form is very similar to Eq. (6), except S(D) is reparametrized in terms of time and is modified by an additional factor which accounts for the rate of cell birth (b) and death (d).
2.B. Coupling MBDCAs with radiobiological models
Calculations of EUBED are highly sensitive to low doses in the dDVH 19, 23, 24 which can reduce EUBED enough to yield a near zero calculated TCP. To circumvent this, previous studies using water-based TG-43 dose distributions first removed low doses (below 110 Gy by King et al. 17 and below D 99 by Ling et al. 13 ) from the dDVH before calculating EUBED, justified by suggesting the low doses typically exist near the periphery of the treatment volume, and subjective contouring should not significantly affect the EUBED calculations. However, MC dose calculations involving heterogeneous tissue models may identify low doses in the prostate interior due to ISA or tissue heterogeneity effects, such as calcification shielding.
MC simulations for 613 PIPB patients were previously carried out using EGSnrc user-code BrachyDose 3 yielding two dose calculation sets: TG43sim, simulating AAPM TG-43 conditions, and, MCDmm, which models tissues, calcifications, and interseed effects with dose scored to the simulated tissues ( Fig. 1 Table II . EUBED >0Gy does not apply any lowdose cutoff, and is used to illustrate EUBED low-dose sensitivity. EUBED >D99 and EUBED >110Gy follow the previous approaches of Ling et al. 13 and King et al., 17 removing doses below D 99 and 110 Gy, respectively. EUBED >110Gy+Edge , EUBED >110Gy+Ca , EUBED >110Gy+LR are modified versions of EUBED >110Gy , each with different additional steps aimed to identify and preserve subsets of low doses which may be of interest to consider in the EUBED calculations. Since EUBED is sensitive to low-dose voxels, we additionally apply a global dose threshold of 72.5 Gy (half the prescription dose) for EUBED >110Gy+Edge , EUBED >110Gy+Ca , and EUBED >110Gy+LR , which does not substantially affect the EUBED calculations for these two patients as they both have a MCDmm and TG43sim V 50 of 99.7% and 100%, respectively. EUBED >110Gy+Edge rejects doses below 110 Gy if they are within a fixed distance from the edge of the prostate, demonstrated using 8 voxels (approximately 2.5 mm). EUBED >110Gy+Ca rejects doses below 110 Gy except those within a distance (8 voxels) of any voxel assigned to calcification. EUBED >110Gy+LR rejects doses below 110 Gy unless the ratio of MCDmm/TG43sim doses is sufficiently low (using a threshold of 0.6), which may identify dose perturbations due to tissue heterogeneities or ISA [Figs. 1(g) and 1(h)]. We do not apply EUBED >110Gy+LR to TG43sim dose calculations since this would be equivalent to EUBED >110Gy . For each method to compute EUBED, TCP P and TCP B are calculated using the values in Table I and an a broadening factor of 0.025 Gy
À1
. For all PIPB patients, several biological dose models are evaluated for each of the MCDmm and TG43sim calculated dose distributions (Table II) 
RESULTS
3.A. Example patients with calcifications
Previous work 3, 25, 26 identified that patients with large calcifications yield the largest dosimetric differences between TG43sim and MCDmm dose calculations. Figure 2 represents the different low-dose voxels rejected in two example patients with large calcifications by the alternate EUBED models described in Table II . EUBED >D99 and EUBED >110Gy , which were previously used 13, 17 to reject low doses near the periphery of the target contour in waterbased models, identify doses to reject in voxels located several millimeters toward the target volume interior with (Table II) 
3.B. Large patient cohort
The results of coupling the various biological dose models with the 613 patient cohort MCDmm and TG43sim dose calculations are summarized in Fig. 3 Average physical dose metrics evaluated with MCDmm are a few percent lower than with TG43sim (average D 90 and V 100 are lower by 5.9% and 2.6% with MCDmm), resulting in similar differences in biological doses: average MCDmm BED NR lower by 5.9%, BED D90 by 7.4%, and EUBED >110Gy by 1.9% (compared with TG43sim). These differences in average biological doses cause differences in TCP estimates, with smaller biological doses leading to larger TCP differences; average MCDmm BED NR TCP P is lower by 1.7%, BED D90 TCP P by 13.4%, and EUBED >110Gy TCP P by 1.9% (compared with TG43sim).
Although the average dose metrics calculated with MCDmm are generally within a few percent of TG43sim, voxel-by-voxel dose distributions can be quite different (Figs. 1(g) and 1(h) ; see also Miksys et al. 3 ). Biological dose models which do not account for dose heterogeneity, such as BED D90 , and do not consider lower dose volumes from tissue heterogeneities or ISA, such as EUBED >110Gy , are well correlated for MCDmm and TG43sim [ Fig. 4(a) ]. However, the modified EUBED models presented herein, which can be sensitive to low doses in MCDmm due to tissue heterogeneity (mainly calcification shielding), can lead to large differences between MCDmm and TG43sim biological doses. These observations are further supported by the consideration of two subsets of patients (25 with calcifications and 25 without) -see Table 1 in Supplementary Materials.
There is a considerable range of biological doses evaluated over the large patient cohort depending on how complicated the model (Fig. 3) . Assuming a uniform dose of D 90 , as done for BED NR , BED D90 and IED D90 , results in biological doses which differ, but are linearly related to each other. However, biological dose models which assume uniform delivery of D 99 or consider dose heterogeneity with EUBED are not linearly related to the uniform D 90 models [ Fig. 4(b) ].
DISCUSSION
4.A. Model-based dose calculations compared with TG-43
This study is the first to explore challenges related to coupling model-based PIPB dose calculations with existing radiobiological models. We have demonstrated new issues to consider when coupling full-tissue model-based dose calculations with existing radiobiological models which are sensitive to low-dose volumes which may result from tissue heterogeneities. Small differences between MCDmm and TG43sim calculated biological doses can lead to large differences in TCP estimates (Fig. 3) .
By studying two example patients with large calcifications we have illustrated that calcification shielding can exist throughout the target volume (Table III) . The local dose differences observed between MCDmm and TG43sim should be reflected in calculations of biological dose, which are only realized with more complicated models that consider dose perturbations from tissue heterogeneities, such as EUBED >110Gy+Edge , EUBED >110Gy+Ca , and EUBED >110Gy+LR [ Fig. 4(a) ].
In TCPs calculated herein for either MCDmm or TG43sim [ranging between 0 and 100% in Fig. 3(b) ] do not accurately reflect patient outcomes. While these have not yet been studied for this cohort of PIPB patients, earlier investigations of low-and intermediate-risk patients from the same institution report 5-year biochemical failure-free survival rates between 87.1% and 90.5%. 27, 28 Larger outcomes studies from other institutions 29-33 report 5-10 yr biochemical failure-free survival rates for similar low to intermediate risk PIPB patients generally in the range of 85-95%. Indeed, investigators 7, 8, 9 have correlated low BED values to poor clinical outcomes, but modeling approaches adopted for those investigations are most similar to BED NR using TG43sim which we have found to be proportional to D 90 and to be the highest estimate of biological dose which yields a TCP of at least 90% for 95% of patients. This suggests a needed to reassess radiobiological model parameter values when coupling heterogeneous tissue model-based dose calculations, such that cohort-average radiobiological model predictions align with clinical observation. However, it would be premature to suggest revised parameters without first performing a detailed outcomes analysis for the patient cohort studied herein, which is left for future work.
4.B. Choice of radiobiological model
Differences between BED and IED, as well as between TCP P and TCP Z , are small compared to the differences due to neglecting cell repopulation or considering dose heterogeneity (Fig. 3) . In addition to calculating IED at 594 days, we calculated IED at T eff = 234.2 days to more directly compare to BED (results not shown) which reduced average IED by less than 1%. This suggests that IED is not overly sensitive to the chosen evaluation time, when taken in context of the other sources of variability between the calculated radiobiological quantities.
Although EUBED has the advantage of accounting for dose heterogeneity, it is limited by sensitivity to the value chosen for dose cutoff (Fig. 5) . We extended the existing EUBED model to differentiate low doses which may be important to consider in radiobiological models. We have presented two methods which rely on the spatial distribution of doses (EUBED >110Gy+Edge , EUBED >110Gy+Ca ), and one method (EUBED >110Gy+LR ) which uses both fully modeled tissue (MCDmm) and water-based (TG43sim) dose calculations. Indeed, EUBED >110Gy+Edge , EUBED >110Gy+Ca , and EUBED >110Gy+LR were quite different than EUBED >110Gy in select highly calcified patients (Table III) . However, when applied across the 613 patient cohort, in which 89.4% of patients had no visible calcifications on postimplant CT images, EUBED >110Gy+Edge , EUBED >110Gy+Ca , and EUBED >110Gy+LR differences with EUBED >110Gy are of the same order as differences between other similar radiobiological models (ex. BED D90 vs BED D99 ) ( Fig. 3 ; Table 1 in Supplementary Materials).
4.C. Sensitivity to assumed model parameters
In this work, we implemented radiobiological models by assuming a particular set of parameter values, but these parameters can vary across patient cohorts and models are sensitive to assumed values.
We adopt a = 0.15 Gy
À1
, based on TG-137 recommendations and the work of Wang et al., 20 but acknowledge a may range between 0.09 and 0.35 Gy
, 4 at least. While biological dose is only slightly dependent on a, TCP is highly dependent, and increasing a, (with a fixed b) can quickly increase TCP [ Fig. 6(a) ].
Cell repopulation is important to consider since neglecting it can cause overestimation of biological dose and TCP [BED NR vs other biological dose models in Fig. 3(a) ]. We assume T pot = 42 days, but T pot may (at least) range from 10 to 60 days. 34 Calculations of EUBED and TCP rapidly decrease [ Fig. 6(b) ] as the assumed rate of cell repopulation increases (T pot decreases). Figure 6 (c) shows that TCP is quickly reduced when the assumed number of cells increases. Additionally, the distribution of evaluated TCPs was largely unaffected when we modified Eq. (7) 
4.D. Radiobiological modeling advancements
Although the mechanistic TCP models presented herein are flexible through their large parameter space, many of the calculated TCPs (TG43sim and MCDmm) using the TG-137-recommended parameter values are unrealistically low (Fig. 3) . We have illustrated in Table III that using a broader TCP B may increase some of the lower calculated TCPs in select calcified patients, but it requires additional knowledge of the effective distribution of a and reduces the higher calculated TCPs. This is consistent with Dasu et al., 1 who show that assuming an a coefficient of variation (standard deviation over the mean) of up to 30% may be needed for realistic TCP modeling, and without it, these models suggest only a very few (as low as 1 in a million) cells which are highly radioresistant (low a) may be the true targets for tumor control.
The MC PIPB dose distributions studied herein may be more accurate than the clinical TG-43 calculations, especially in patients with calcifications, but they are also limited by their assumption of a static patient geometry defined by 30-day postimplant CT images. In reality, the majority of dose delivery is within the first weeks after treatment when edema can considerably change the patient geometry. [35] [36] [37] The sensitivity of the radiobiological indices to the spatial distribution of doses within the treatment volume supports the need for research toward dynamic 4D model-based dose calculations for brachytherapy.
All of the radiobiological models studied herein are limited by their assumption that tumor cells are uniformly distributed throughout the entire prostate volume. Several publications using histology data have identified that subvolumes of the prostate have different probabilities of containing tumor cells. [38] [39] [40] The work of Haworth et al. 14, 15 has presented an advanced radiobiological modeling approach which incorporates these data to account for tumor cell heterogeneity. However, this approach relies on population-based tumor distributions and does not describe the tumor heterogeniety for any given patient. Fortunately, many institutions are now moving toward focal therapies and acquiring multiparametric MRI (mpMRI) 41, 42 to identify patient-specific prostate subvolumes which contain cancerous cells. The development of mpMRIguided heterogeneous tumor burden biological dose and TCP models will contribute to the advancement of PIPB radiobiological modeling. The models presented herein, which consider heterogeneous dose distributions and aim to identify critical low-dose subvolumes, emphasize the importance of such research and may be useful tools for retrospective studies using patient data lacking differentiated tumor subregions.
CONCLUSIONS
Estimated biological doses and TCPs for PIPB differ considerably with choice of radiobiological model. Since 125 I PIPB dose distributions are highly heterogeneous and dose is delivered over several weeks, models should consider cell repopulation and dose heterogeneity. However, existing models which satisfy these criteria, such as EUBED, are limited by their sensitivity to small low-dose volumes. Existing approaches to neglect these low doses may no longer be justified when coupling these models with model-based dose calculations which can identify clinically relevant low-dose volumes resulting from tissue heterogenieties and ISA, with largest effects due to calcification shielding. Our extensions to EUBED consider the spatial distribution of doses, enabling inclusion of low doses resulting from tissue heterogeneities which can have substantial effects on biological dose and TCP estimates. Moderate differences between PIPB waterbased TG-43 and heterogeneous tissue model-based dose calculations can translate into large differences in TCP estimates, especially for lower estimates of biological dose. However, the differences between radiobiological indices between water-based and full-tissue dose calculations is shadowed by the dependence of these radiobiological models on which model is implemented and choice of parameter values. Recommended radiobiological parameter values may require readjustment to align average model predictions with observed treatment outcomes when biological dose and TCP estimates are derived from MC, rather than TG-43, dose calculations. Despite current limitations, these radiobiological models may continue to be valuable tools to relatively compare different dose distributions. Nevertheless, radiobiological indices studied herein (BED, IED, EUBED, and TCP) are sensitive to dosimetric differences caused by tissue heterogeneity (mainly from calcifications) which underlines the importance of clinically adopting model-based dose calculations for PIPB.
